Previous 10 | Next 10 |
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced participation at several upcoming investor conferences. Details of each presentati...
Tenaya Therapeutics (TNYA -13.0%), which has several gene therapy candidates in preclinical development, is down ssignificantly today. As of 119p, volume was ~40.8K shares. Average daily volume is ~137.1K shares. Last month, Zacks Investment Research upgraded shares from sell to hold. One of ...
The following slide deck was published by Tenaya Therapeutics, Inc. in conjunction with this event. For further details see: Tenaya Therapeutics (TNYA) Investor Presentation - Slideshow
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced changes to its Board of Directors including the addition of June Lee, M.D., and the tr...
Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that Faraz Ali, Chief Executive Officer, will participate in the following conference...
Tenaya Therapeutics (NASDAQ:TNYA): Q3 GAAP EPS of -$0.68 beats by $0.20. Press Release Cash, cash equivalents and investments in marketable securities of $280.5 million For further details see: Tenaya Therapeutics EPS beats by $0.20
- Initiated global natural history study for pediatric patients with MYBPC3 mutation to support clinical development of TN-201 gene therapy - Presented preclinical data supporting both TN-201 and PKP2 gene therapy programs at the European Society of Gene and Cell Therapy confe...
Gainers: Autolus Therapeutics AUTL +33%, PetVivo PETV +21%, Cronos (NASDAQ:CRON) +19%, Tenaya Therapeutics (NASDAQ:TNYA) +16%, Privia Health PRVA +13%. Losers: GT Biopharma (NASDAQ:GTBP) -29%, Ontrak (NASDAQ:OTRK) -19%, Molecular Partners...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Tenaya Therapeutics, Inc. (NASDAQ:TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced today that it will present new preclinical data at the virtual 28th Annual Congress of the E...
News, Short Squeeze, Breakout and More Instantly...
Tenaya Therapeutics Inc. Company Name:
TNYA Stock Symbol:
NASDAQ Market:
Tenaya Therapeutics Inc. Website:
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role Pediatric Cardiologist and Genetic Therapy Expert Barry J. Byrne, M.D., Ph.D., Joins Scientific Advisory Board Board Member Jin-Long Chen, Ph.D., Steps Down ...
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that ...
2024-06-10 07:30:04 ET William Blair analyst issues OUTPERFORM recommendation for TNYA on June 10, 2024 05:41AM ET. TNYA was trading at $3.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recomm...